Recent Investment Analysts’ Ratings Updates for Arcus Biosciences (RCUS)

A number of firms have modified their ratings and price targets on shares of Arcus Biosciences (NYSE: RCUS) recently:

• 8/10/2026 – Arcus Biosciences was given a new $23.00 price target by Morgan Stanley.
• 8/7/2026 – Arcus Biosciences had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $42.00 price target on the stock.
• 8/6/2026 – Arcus Biosciences had its price target raised by Wedbush from $41.00 to $43.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – Arcus Biosciences had its price target raised by Wells Fargo & Company from $23.00 to $26.00. They now have an “equal weight” rating on the stock.
• 7/20/2026 – Arcus Biosciences had its price target raised by HC Wainwright from $32.00 to $45.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Arcus Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling

In other news, CAO Alexander Azoy sold 2,562 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $25.77, for a total transaction of $66,022.74. Following the completion of the transaction, the chief accounting officer directly owned 39,581 shares in the company, valued at approximately $1,020,002.37. The trade was a 6.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Juan C. Jaen sold 20,067 shares of the stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $28.62, for a total value of $574,317.54. Following the completion of the transaction, the president directly owned 822,240 shares of the company’s stock, valued at $23,532,508.80. This trade represents a 2.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 102,562 shares of company stock worth $2,975,354. Corporate insiders own 7.60% of the company’s stock.

Get Arcus Biosciences Inc alerts:

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.

Featured Stories

• Five stocks we like better than Arcus Biosciences
• The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
• Sociedad Química y Minera’s Lithium Boom Is Back, But Iodine Steals the Show
• Forget Chips: These 3 Stocks Are Building the AI Data Center Boom
• AIxCrypto Dumps Its Crypto and Goes All In on Robotics

Receive News & Ratings for Arcus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.